CD8A and COVID-19: Although cellular immune responses are important for the protection of some vaccines, most vaccines licensed today, including COVID‐19 vaccines, protective efficacy depends primarily on the induction of neutralizing antibodies.[12, 13] Nanoparticle vaccines functionalized with mAbs that bind to receptors on CD8α− DCs (e.g., CD11b)[14] or both CD8α+ and CD8α− DCs (e.g., CD11c)[15] might increase antigen delivery and presentation to CD4+ T cells, driving enhanced antibody immunity via the provision of high‐quality T cell help.